Ostarine MK-2866 - 100 Tablets

In stock

Lab tested · Dec 2025
£44.95

Ostarine (MK-2866), also called enobosarm, in a pouch of 100 tablets of 10mg each. It is a non-steroidal SARM from the arylpropionamide series, originated by GTx, and is among the most clinically studied compounds of its class. Sold as a reference material for laboratory research.

Supplied for Research Purposes Only This information and product is provided for research purposes only. We do not provide any advice on the usage of these products. These products are for sale to persons aged 18 and over only. Customers should check the legality of this product in their own country prior to purchase.

Certificate of analysis

Independently tested by MZ Biolabs

All lab reports
View full certificate from 10 December 2025 (PDF, opens in a new tab)

Latest result

Most recent test
  • 90% Of expected amount 9 mg measured, 10 mg expected
Sample tested
Finished product
Analysis date
10 December 2025
Laboratory
MZ Biolabs
Lab lot
2025-11-21
Identity
Molecular weight confirmed
Method
HPLC-UV-MS

Testing history

  1. 10 December 2025 90% of expected · Finished product PDF
  2. 7 March 2023 Purity 99.51% PDF
  3. 20 February 2022 Purity 99.88% PDF
  4. 10 June 2021 Purity 100% PDF

Ostarine: enobosarm, MK-2866 and GTx-024 are one compound

Why it has so many names

Few research compounds carry as many labels as this one, and each marks a stage in its history. GTx-024 was the code used by GTx, Inc., the company that originated it. MK-2866 dates from the period when the compound was licensed to Merck. Enobosarm is its international non-proprietary name, and Ostarine was GTx's own brand name. S-22 is the designation from the arylpropionamide series that also produced andarine (S-4) and S-23.

  • MK2866
  • Enobosarm
  • GTx-024
  • S-22

Research history

Ostarine is a non-steroidal selective androgen receptor modulator. The preclinical studies established its binding to the androgen receptor and compared responses in muscle, prostate and bone tissue in rats, the same design used for andarine before it. Ostarine then went further into human research than other SARMs. It has been investigated in clinical trials in muscle wasting associated with cancer and, more recently, in androgen receptor positive breast cancer. No regulator has licensed it as a medicine, and it is sold here only as a research reference material.

Contents and storage

The pouch contains 100 Dynamic Performance tablets, each with 10mg of Ostarine MK-2866. Keep it sealed in a cool, dry place and protect it from light. The tablets are intended for laboratory use as a reference material, for example in analytical method work.

Products are supplied for research purposes only and are for sale to persons aged 18 and over.